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Abstract
Introduction. Obesity’s influence on the effectiveness of electrical cardioversion (CVE) still requires more studies. The 
study aimed to evaluate the impact of obesity on the efficacy of CVE in atrial fibrillation (AF).
Material and methods. Eighty-nine patients [female/male (F/M): 33/56; mean age: 64.66 ± 9.7 years) with persistent 
symptomatic AF qualified for CVE were prospectively enrolled in the study. CVE efficacy was analyzed immediately after 
the procedure and in a one-month follow-up. Patients with immediately efficient CVE were divided into obese group 
[OG; body mass index (BMI) ≥ 30 kg/m2, 49 patients, F/M: 21/28, mean age: 64 ± 10 y.] and non-obese group (NOG; 
BMI < 30 kg/m2, 33 patients, F/M: 9/24, mean age: 66 ± 10 y.).
Results. Immediate CVE efficacy was 92%. Sinus rhythm restoration was not BMI-dependent, but BMI had an impact 
on the amount of energy needed for sinus rhythm restoration (150 J in NOG vs. 200 J in OG, p < 0.05). One-month 
CVE efficacy was 47%: 38.8% in OG and 60.6% in NOG (p < 0.05). Patients in OG had greater left atrium (LA) and left 
ventricle (LV) diameters (p < 0.05) and lower LV ejection fraction (EF) (p < 0.05) as compared to NOG subjects. Logistic 
regression analysis revealed LV EF (odds ratio: 1.107, 95% CI: 1.015–1.207, p < 0.05] as a factor influencing one-month 
CVE efficacy.
Conclusions. Immediate high efficacy of CVE in persistent AF seems to be independent of coexisting obesity, however, 
obesity has an impact on the amount of energy needed for sinus rhythm restoration. One-month efficacy of CVE is low 
and modified by coexisting obesity.
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KNW/022/KB1/159/16/17, 31.01.2017) and has been 
performed in accordance with the ethical standards laid 
down in the 1964 Declaration of Helsinki. Patients qua-
lified for the study gave their informed consent prior to 
their inclusion.
Body measurements
Every patient underwent weight measurements on a balan-
ced beam scale and height measurements with a stadiome-
ter. Waist circumference was measured at a level midway 
between lower rib margin and the iliac crest, while hip 
circumference was measured as maximal circumference 
over the buttocks. BMI was calculated by dividing patients’ 
weight in kilograms by height in meters squared, while body 
surface area (BSA) was obtained by Mostellar formula. The 
waist-to-hip ratio (WHR) was obtained by dividing waist 
circumference by hip circumference.
Laboratory testing
On admission, all of the patients qualified for CVE unde-
rwent basing laboratory testing. Blood samples for the 
laboratory testing were collected from the antecubital vein.
Echocardiography
All of the patients underwent transthoracic echocardiograp-
hy before CVE by a single experienced investigator using an 
Epiq 7G (Philips, Andover, MA, USA) with a 2.5-MHz probe 
in 2D, M and Doppler modes.
Definitions
AF was defined by arrhythmia lasting at least 30 seconds 
with a typical pattern of irregular RR intervals and no 
discernible, distinct P waves observed in ECG [6]. Arterial 
hypertension was defined as newly recognised hyperten-
sion based on two separate measurements that exceeded 
140/90 mm Hg during the hospitalisation, a previous 
hypertension diagnosis or any antihypertensive drug use 
[7]. Diabetes mellitus was defined as the fasting blood 
glucose levels over 125 mg/dL in two separate measure-
ments or in the case of the use of hypoglycaemic agents. 
Impaired fasting glucose and impaired glucose tolerance 
were analysed jointly with diabetes mellitus [8]. Estimated 
glomerular filtration rate (eGFR) calculated according to 
the Cockcroft-Gault formula including the creatinine level, 
patient age, sex and weight was used to represent patients’ 
kidney function.
Electrical cardioversion procedure
Every patient qualified for CVE was administered vitamin K 
agonist or new oral anticoagulant for at least three weeks. 
CVE was performed by an experienced physician in short-
-term intravenous anaesthesia until sinus rhythm resto-
ration with an increasing amount of energy starting from 
150 J using paddles. Antero-lateral position of paddles was 
Introduction
Despite growing consciousness of the issue, the prevalence 
of obesity has doubled in more than 70 countries during 
the last 30 years [1].
Obesity is a well-known risk factor for cardiovascular 
diseases including atrial hypertension, dyslipidemia, dia-
betes, stroke, coronary artery disease and arrhythmias [2].
Constant low-grade inflammation, structural remodel-
ling including enlargement, fibrosis and fatty infiltration of 
the atrium observed in obesity are the main mechanisms 
of atrial fibrillation (AF) pathogenesis in this group of pa-
tients [3].
The impact of obesity on electrical cardioversion (CVE) 
outcomes, which is a method of choice in symptomatic pa-
tients, is uncertain. Some studies suggest lower CVE effica-
cy in obese patients and a higher risk of AF recurrence after 
sinus rhythm restoration [4]. Structural changes including 
left ventricular hypertrophy and left atrium enlargement, 
observed in the previous studies, could play an important 
role in that issue. On the other hand, fatty tissue reduction 
itself probably could reduce the AF recurrence rate [5].
Taking into account the increasing number of obese 
patients with AF, the study aimed to evaluate the impact 
of obesity on the efficacy of CVE.
Material and methods
Eighty-nine patients with persistent symptomatic AF who 
had been qualified for electrical cardioversion were pro-
spectively enrolled in the study. The presence of the symp-
tomatic AF documented by an electrocardiogram (ECG) 
was the main inclusion criterion for the study. The primary 
endpoint of the study was the presence of AF in the ECG 
performed immediately after CVE or sinus rhythm absence 
at a one-month follow-up. Patients on antiarrhythmic treat-
ment with amiodarone, with active inflammatory disease, 
chronic kidney disease with estimated glomerular filtration 
rate < 30 mL/min/1.73 m2, severe valvular heart disease, 
left ventricle ejection fraction < 40%, cardiomyopathy, 
diabetes mellitus demanding insulin therapy and patients 
with morbid obesity [body mass index (BMI) ≥ 40 kg/m2) 
were excluded from the study.
On the day of CVE, patients underwent clinical examina-
tion, including the collection of anthropometric data, labo-
ratory testing, ECG and echocardiography (ECHO).
Patients without sinus rhythm restoration were no lon-
ger observed, while those with successful CVE took part 
in a one-month follow-up. Body mass index, which con-
stituted a discriminating factor for the study groups, was 
≥ 30 kg/m2 in the obesity group (OG) and < 30 kg/m2 in 
the non-obese group (NOG).
The study has been approved by the ethics committee 
(Bioethical Committee, Medical University of Silesia; No 
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used both in first and in subsequent shocks with no change 
to antero-posterior position after unsuccessful shock. The 
performing physician decided on the energy of subsequent 
shocks taking into account patients clinical characteristics 
(BMI, FA duration). If CVE was not successful after three 
attempts the procedure was ended.
Before termination of hospitalization, the changes re-
quired from previous treatment were made.
Statistical analysis
Statistical analysis was performed by Statistica 13.0 
(TIBCO Software Inc., Palo Alto, CA, U.S.) and StataSE 13.0 
(StataCorp LP, TX, U.S.) software. Statistical significance 
was set at a p value below 0.05. All tests were two-tailed. 
Variables were presented as mean value ± standard de-
viation (SD) in case of normal data distribution or median 
with lower and upper quartile for other distributions or as 
a number and percentage for data in nominal and ordinal 
scale. The distribution of variables was evaluated by the 
Anderson-Darling test and the quantile-quantile (Q-Q) plot. 
The homogeneity of variances was assessed by the Levene 
test. The t-Student’s test was performed to compare two 
independent groups (according to BMI ≥ 30 kg/m2 and 
below) for normally distributed data and in case of non- 
-normal distribution, the U Mann-Whitney test was used. 
For nonparametric data χ2 test was performed. Logistic 
regression was used to calculate risk factors of higher 
energy used for effective CVE (> 200 J) and to assess CVE 
efficiency. Results were presented as odds ratios with 95% 
confidence intervals (CI) and corresponding p-value.
Results
Demographic and clinical characteristics  
of the population qualified for CVE
The study group consisted of eighty-nine patients.
Immediate CVE efficacy reached 82 subjects, only in 
7 individuals, the procedure did not restore sinus rhythm. 
The group of patients with inefficient CVE did not signifi-
cantly differ in BMI or age from the group with a successful 
procedure outcome (Figure 1).
Demographic and clinical characteristics  
of patients with effective CVE
The OG consisted of 49 individuals, while 33 subjects were 
included in the NOG.
Both OG and NOG were symptomatic (median EHRA 
score: 2 in OG and NOG), with a moderate risk of thrombo-
embolism (median CHA2DS2-VASc: 3 in OG and NOG). The 
most prevalent comorbidities in both groups were atrial hy-
pertension (92%), hyperlipidemia (52%), diabetes mellitus 
(33%) and coronary artery disease (28%). Nearly 14% of the 
patients had already experienced a stroke or TIA episode.
More than half of the participants were taking angio-
tensin-converting enzyme (ACE) inhibitors, beta-blockers, 
statins and diuretics. Dabigatran was the most frequently 
used anticoagulant drug (40% vs. 34% for rivaroxaban, 
20% for acenocoumarin, 3% for warfarin and apixaban). 
Despite implemented therapy blood pressure exceeding 
the norm was observed in 22% of patients during hospi-
talization.
Figure 1. A diagram representing a course of the study; F — female; M — male; BMI — body mass index; CVE — electrical cardioversion
CVE
Population enrolled in the study
N = 89
F/M = 33/56
2BMI = 31.90 ± 5.9 kg/m
Age = 64.66 ± 9.7
Effective
N = 82 (92%)
F/M = 30/52
2BMI = 31.56 ± 5.7 kg/m
Age = 64.78 ± 9.9 
Ineffective
N = 7 (8%)
F/M = 3/4
2BMI = 35.85 ± 7.7 kg/m
Age = 63.29 ± 7.5 
One-month folllow-up
2BMI ≥ 30 kg/m 2BMI < 30 kg/m
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Only 9% of patients admitted to smoking cigarettes and 
1% to abuse alcohol.
In the study, CVE turned out to be safety a safety pro-
cedure. None of the adverse events including skin burns 
and embolic complications was observed.
Anthropometric measurements
OG and NOG differed significantly not only in weight and 
BMI (33.4 kg/m2 vs. 27.1 kg/m2) but also in BSA and waist 
circumference.
Laboratory testing
Laboratory tests showed no significant differences in me-
asured parameters between groups. Measured levels of 
glucose were exceeding recommended values in both of 
the study groups (Table S1).
Echocardiography
Left ventricle end-diastolic diameter (LV EDD), LV end-
-systolic diameter (LV ESD), but also LV end-diastolic and 
end-systolic volumes (LV EDV, LV ESV) were significantly 
different between the study groups (p < 0.05). The study 
revealed that left atrial antero-posterior diameter (LA) 
as well as left atrial area (LA area) and left atrial volume 
(LA volume) had greater values in OG comparing to NOG 
(p < 0.05) (Table S2).
Patients in OG had significantly lower LV ejection fra-
ction (LV EF) comparing to NOG patient (p < 0.05).
The study groups did not differ in other diastolic fun-
ction markers like E/E’, deceleration time (DT) or isovolu-
metric relaxation time (IVRT) measured in ECHO. Also, the 
frequency of the mitral valve regurgitation was similar in 
both groups.
Table S1. Baseline clinical characteristics of obese group (OG) and non-obese group (NOG) — laboratory testing
Variable Absolute count and percentage or median (25–75 percentile) 






Platelet count [×1000/mm3] 217.5 (59.1) 224.7 (47.1) 0.69
Hemoglobin concentration [g/dL] 14.3 (1.3) 14.6 (1.6) 0.35
White blood cells [×1000/mm3] 7.1 (1.9) 6.9 (1.8) 0.69
Serum creatinine concentration [mg/dL] 0.98 (0.18) 0.94 (0.15) 0.35
eGFR [mL/min/1.73 m2] 75.4 (11.4) 78.8 (9.4) 0.16
Glucose [mg/dL] 108.0 (98.0–124.8) 100.0 (92.0–114.0) 0.06
Total cholesterol [mg/dL] 163.8 (44.9) 176.6 (43.5) 0.21
Low-density lipoprotein (LDL) [mg/dL] 86.4 (39.1) 96.2 (38.3) 0.28
High-density lipoprotein (HDL) [mg/dL] 50.7 (15) 54.2 (15.7) 0.32
Triglycerides [mg/dL] 129 (100–151) 109 (83–157) 0.88
eGFR — estimated glomerular filtration rate
Table S2. Baseline clinical characteristics of obese group (OG) and non-obese group (NOG) — echocardiography
Variable Absolute count and percentage or median (25–75 percentile)  






LA antero-posterior diameter [mm] 44.8 (4.9) 42.4 (5.2) < 0.05
LA area [cm2] 26.1 (4.2) 24.2 (4.1) < 0.05
LA volume [mL] 83.9 (18.1) 75.2 (20.9) < 0.05
LV EF [%] 54.8 (5.4) 57.7 (5.8) < 0.05
LV EDD [mm] 51.9 (5.4) 48.9 (4.4) < 0.01
LV ESD [mm] 33.2 (5.7) 30.4 (4.5) < 0.05
LV EDV [mL] 133.8 (36.5) 110.3 (27.5) < 0.01
LV ESV [mL] 60.1 (19.9) 47.5 (14.8) < 0.01
LA — left atrial; LV — left ventricle; EF — ejection fraction; EDD — end-diastolic diameter; ESD — end-systolic diameter; EDV — end-diastolic volume; ESV — end-systolic volume
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Energy used for effective CVE
The study showed significantly higher energy needed for 
sinus rhythm restoration in OG (median: 200 J vs. 150 J) 
(Table 1).
The logistic regression model revealed that higher BMI, 
BSA and waist circumference had an impact on the amount 
of energy needed for efficient CVE (Table S3). Echocardio-
graphic parameters including left heart dimensions, presence 
Table 1. Demographic and clinical characteristics of obese and non-obese group of patients with effective sinus rhythm restoration
Variable Absolute count and percentage or median  
and 25–75 percentile or mean ± standard deviation
p
BMI ≥ 30 kg/m2 
N = 49
BMI < 30 kg/m2 
N = 33
Age [years] 64 (10) 66 (10) 0.02
Sex (F/M) 21/28 9/24 0.15
Weight [kg] 97 (89–108) 80 (69–85) < 0.001
Height [cm] 1.69 (10) 1.7 (8) 0.2
BMI [kg/cm2] 33.4 (31.9–36.8) 27.1 (24.2–28.7) < 0.001
BSA [m2] 2.26 (0.25) 1.91 (0.17) < 0.001
Waist circumference [cm] 113.2 (12.7) 96.3 (11.6) < 0.001
WHR 0.98 (0.9–1.06) 0.96 (0.87–1.02) 0.44
CHA2DS2-VASc (pts) 3.0 (1.6) 3.0 (1.7) 0.94
EHRA score 2 (2–2) 2 (2–2) 0.77
Beta-blockers therapy before CVE 42 (85.7%) 23 (69.7%) 0.09
Non-amiodaron antiarrhythmic therapy before CVE
Sotalol therapy 2 (4.8%) 5 (15%) 0.1
Propafenone therapy 2 (4.1%) 3 (9.1%) 0.39
CVE immediate efficacy 49 (89%) 33 (97%) 0.8
Energy used for effective CVE [J] 200 (200–200) 150 (150–200) < 0.001
Beta-blockers therapy after CVE 41 (83%) 21 (63%) 0.07
Non-amiodaron antiarrhythmic therapy after CVE
Sotalol therapy after CVE 2 (4.8%) 5 (15%) 0.1
Propafenone therapy after CVE 2 (4.1%) 3 (9.1%) 1.0
CVE efficacy in one-month follow-up 19 (38.8%) 20 (60.6%) < 0.05
BMI — body mass index; F — female; M — male; BSA — body surface area; WHR — waist-to-hip ratio; EHRA — European Heart Rhythm Association; CVE — electrical cardioversion
Table S3. Energy used to sinus rhythm restoration and clinical characteristics of the study group
Variable OR –95% CI +95% CI p
Age (years) 0.963 0.915 1.014 0.15
BSA [m2] 1.555 1.192 2.030 < 0.001
BMI [kg/m2] 1.458 1.221 1.740 < 0.001
WHR 1.049 0.683 1.611 0.83
Waist circumference [cm] 1.082 1.034 1.132 < 0.01
LA [mm] 1.086 0.986 1.197 0.09
LA area [cm2] 1.013 0.906 1.132 0.22
LA vol [mL] 1.013 0.988 1.039 0.29
LAVI [ml/m2] 0.986 0.941 1.033 0.57
E/E’ 0.029 0.001 39.505 0.34
Mitral insufficiency grade 2.000 0.733 5.453 0.18
OR — odds ratio; CI — confidence interval; BSA — body surface area; BMI — body mass index; WHR — waist-to-hip ratio; LA — left atrium; vol — volume; LAVI — left atrial volume index; E/E’ — mitral peak veloc-
ity of early filling to early diastolic mitral annular velocity
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of mitral valve regurgitation and other markers of diastolic 
function had no influence on energy used for effective CVE.
One-month follow-up results
At the one-month follow up only 47.5% of patients who 
experienced a successful sinus rhythm restoration remai-
ned free of arrhythmia. One-month CVE efficacy was 38.8% 
in OG and 60.6% in NOG with (p < 0.05).
Blood pressure exceeding over 140/90 mm Hg was still 
observed in 17% of patients during physical examination. 
Despite the recommendation only 4 patients (5%) man-
aged to reduce weight, the rest maintained or even gained 
weight. There were no patients who managed to give up 
smoking in the whole observed population.
CVE efficacy — logistic regression analysis
Logistic regression analysis revealed that clinical cha-
racteristics and echocardiographic parameters have no 
significant impact on immediate CVE efficacy. The BMI 
values showed a favourable trend to influence immediate 
CVE efficacy (Table 2).
Logistic regression analysis revealed that LV EF influ-
ences one-month CVE efficacy (Table 2).
There were no independent factors related to immedia-
te and one-month CVE efficacy.
Discussion
While the impact of obesity on AF pathogenesis is well 
known, the influence of the excessive fatty tissue on 
antiarrhythmic treatment with CVE both immediate and 
long-term is uncertain. In our study, immediate procedure 
efficacy in patients qualified for CVE reached 92% and 
was not BMI dependent. The results of our study stay in 
opposition to the previous research.
In the multicenter prospective trial ENSURE-AF by Lip 
et al. [9] clinical factors affecting CVE efficacy as well as 
adverse events of anticoagulation therapy were analyzed. 
In ENSURE-AF 2,199 patients were randomized to endo-
xaban or enoxaparin- warfarin group. CVE was successful 
in 1,578 patients (72%), in 355 individuals procedure did 
not restore sinus rhythm. Patients with inefficient CVE 
were characterized by higher BMI as well as higher body 
weight compared to the patients with successful rhythm 
restoration. Male sex, coronary artery disease, acetylsali-
cylic acid and statin therapy were also more common in 
patients with inefficient CVE. Multivariate analysis revealed 
BMI, weight and gender as an independent predictor of 
successful CVE. In our study, immediate CVE efficacy was 
independent of BMI.
All of the patients enrolled in the study underwent a CVE 
procedure with shocks delivered by paddles. Many medical 
centres prefer using patches as a modality of CVE due to 
convenience. However, this could result in lower immediate 
CVE efficacy especially in the obese population.
While CVE is a highly efficient procedure for most pa-
tients, in the obese population, there are some technical 
aspects of the intervention that should be taken into consi-
deration. Deposits of the excessive fatty tissue, resulting in 
higher transthoracic impedance, are the reason why some 
modifications of techniques need to be implemented. In 
obese patients, the choice between using adhesive pat-
ches and handheld paddles, which apply pressure to the 
chest wall properly, prove that choosing the most efficient 
shock vector and the adjustment of energy delivered play 
an invaluable role.
Table 2. Logistic regression of clinical characteristics and echocardiographic parameters influencing immediate and one-month electrical 
cardioversion (CVE) efficacy
Variable Immediate CVE efficacy One-month CVE efficacy
OR –95% CI +95% CI p OR –95% CI +95% CI p
Age [years] 1.015 0.940 1.097 0.7 1.036 0.990 1.035 0.13
BSA [m2] 0.276 0.014 5.274 0.39 0.406 0.68 2.401 0.32
BMI [kg/m2] 0.908 0.815 1.012 0.08 0.961 0.888 1.041 0.33
WHR 1.349 0.625 2.907 0.44 0.858 0.575 1.281 0.46
Waist circumference [cm] 0.967 0.920 1.015 0.18 0.983 0.954 1.014 0.28
LA [mm] 0.942 0.809 1.096 0.44 0.912 0.831 1.001 0.052
LA area [cm2] 0.991 0.828 1.186 0.92 0.947 0.853 1.051 0.31
LA vol [mL] 0.983 0.945 1.022 0.39 0.979 0.956 1.022 0.08
LAVI [ml/m2] 0.982 0.910 1.059 0.64 0.973 0.930 1.017 0.23
LV EF [%] 1.114 0.980 1.267 0.1 1.107 1.015 1.207 < 0.05
E/E’ 1.657 0.180 15.271 0.66 1.687 0.529 5.382 0.38
Mitral insufficiency grade 0.396 0.45 3.467 0.4 1.141 0.438 2.989 0.79
OR — odds ratio; CI — confidence interval; BSA — body surface area; BMI — body mass index; WHR — waist-to-hip ratio; LA — left atrium; vol — volume; LAVI — left atrial volume index; LV EF — left ventricular 
ejection fraction; E/E’ — mitral peak velocity of early filling to early diastolic mitral annular velocity
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In the study by Voskoboinik et al. [10] energy used for 
CVE in patients with BMI ≥ 30 kg/m2 and modality (patches 
and paddles) were analyzed. The energy used for the first 
shock was 100 J and 200 J for the second shock if needed. 
If the two shocks failed, patients underwent a third shock 
using alternative modality and 200 J energy. CVE was effi-
cient in the first (100 J) or second (200 J) shock in 90.3% 
while using paddles and only in 68.2% with patches. There 
were 20 crossovers from patches to paddles and six from 
paddles to patches. In the whole obese population, CVE 
with paddles was effective in 82.9%, while with patches 
only in 66.7%.
In the study by Kang et al. [11] more than one-third of 
patients enrolled in the study experienced AF recurrence 
in follow-up after ablation. Patients with efficient ablation 
were characterized by lower BMI, shorter duration of AF 
and lower prevalence of diabetes mellitus. What’s more to-
tal number of shocks during CVE preceding ablation, total 
energy and the highest shock energy were lower in patients 
maintaining sinus rhythm in follow-up. These observations 
suggest that CVE energy parameters may be related to the 
electroanatomical remodelling of AF and could predict AF 
recurrence after ablation.
According to the previous observations, obesity is the 
main risk factor for LA enlargement [12]. In our study, OG 
was characterized by greater LA measurements observed 
by echocardiography comparing to the NOG. This data is in 
agreement with well-recognized observations that obesity 
may be a cause of LA dilatation.
In the study by Stritzke et al. [13] over 1200 partici-
pants were observed for 10 years to find out which factor 
has the strongest impact on LA volume, focusing especially 
on obesity and atrial hypertension. Follow-up revealed that 
both high BMI and hypertension results in LA enlargement, 
but obesity impact was the greatest.
Association between obesity and left ventricle hyper-
trophy had already been described in various publications. 
In the study issued in “Hypertension”, BMI was a predictor 
of left ventricle enlargement and myocardial dysfunction ex-
pressed in decreased midwall fractional shortening without 
significant impact on ejection fraction [14].
In contrast to some previous publications [15], our stu-
dy showed that patients with BMI ≥ 30 kg/m2 were cha-
racterized by lower ejection fraction comparing to NOG.
In the study by Morricone et al. [16], obese patients 
not only had significantly larger left ventricular diameters, 
but also thicker end-diastolic septum and posterior wall 
coupled with impaired diastolic function. However, in our 
study, there were no significant differences in diastolic 
function markers.
The study revealed that the average energy needed 
for effective cardioversion in OG was higher than in NOG. 
While the median energy value for patients with BMI 
≥ 30 kg/m2 reached 200 J, patients with lower BMI needed 
only 150 J. In the logistic regression model, not only BMI 
but also BSA and waist circumference were related to the 
necessity to use higher energies.
To limit a potent amiodaron influence on CVE efficacy 
patients on antiarrhythmic therapy with amiodaron were 
excluded from the study. Some of the patients were recei-
ving other antiarrhythmic drugs (sotalol, propafenone) befo-
re CVE and the therapy was maintained after the procedure.
Obesity influence on long-term CVE outcomes still re-
quires continued study. What we can prove is constant low-
-grade inflammation, insulin resistance and maladaptive 
immune responses are responsible for higher cardiovascu-
lar risk observed in obese patients.
In the study by Guglin et al. [4], the effect of obesity on 
AF recurrence was analyzed using data from the Atrial Fi-
brillation Follow-Up Investigation of Rhythm Management 
(AFFIRM) study. Higher BMI was associated with a higher 
number of cardioversions (OR 1.017 for a BMI increase of 
1 kg/m2) but also with a higher risk of being in AF on fol-
low-up. Also, LA measurements and history of hyperten-
sion were the risk factors of AF recurrence. However, the 
multivariate analysis revealed that LA size but not BMI was 
an independent predictor of AF recurrence. According to 
previous publications covering this subject, the effect of 
obesity on AF efficiency was related to the greater LA me-
asurements in patients with higher BMIs. This finding is 
consistent with the results of our study.
The discussion should take into consideration data on 
the implementation of lifestyle modification. It is emphasi-
zed in many publications that the role of weight manage-
ment is not only in AF recurrence rate [17–19] but also in 
relieving the symptoms. In the study published in “JAMA”, 
patients randomized to a weight management group sho-
wed a significantly greater reduction in the number of AF 
episodes, but also in syndrome severity scores than the 
control group. Furthermore, patients in the weight mana-
gement group had lost weight more effectively than the 
group which received only general lifestyle advice. Ad-
ditionally, weight reduction was associated with reverse 
cardiac remodelling. Reduction in intraventricular septal 
thickness and left atrial area was observed only in the in-
tervention group [5].
The limited number of enrolled patients combined with 
the measurement error in anthropometry and echocardio-
graphy were the main limitations of the study. Assessment 
of some of the technical differences, for example, the pres-
sure applied to the chest wall during the CVE procedure 
was practically impossible.
Conclusions
Proper qualification for CVE and careful course of proce-
dure resulted in high immediate efficacy of intervention 
even in obese patients. While higher energy usage could 
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be necessary, greater amounts of delivered shocks should 
be taken into consideration.
A Long-term efficacy of CVE is still insufficient and se-
ems to be worse in obese patients.
The borderline influence of BMI on immediate CVE ef-
ficacy and low one-month CVE efficacy in obese subjects 
suggest that further studies are necessary. BMI impact on 
the amount of energy needed for sinus rhythm restoration 
and bigger LA diameters in obese patients constitute the 
next argument in the discussion regarding obesity and si-
nus rhythm restoration.
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Streszczenie
Wstęp. Znaczenie otyłości dla efektywności procedur przywracających rytm zatokowy nie zostało nadal jednoznacznie 
określone. Celem przeprowadzonego badania była ocena wpływu otyłości na skuteczność kardiowersji elektrycznej (CVE) 
w migotaniu przedsionków (AF).
Materiały i metody. Do badania włączono 89 pacjentów zakwalifikowanych do CVE z powodu objawowego przetrwałego 
AF. Pacjentów, u których przywrócono rytm zatokowy, podzielono na 2 grupy, uwzględniając ich wskaźnik masy ciała 
(BMI): grupę z otyłością (OG: BMI ≥ 30 kg/m2) i bez otyłości (NOG: BMI < 30 kg/m2). W obu grupach ponownie oceniono 
skuteczność CVE po miesiącu obserwacji.
Wyniki. Natychmiastowa skuteczność CVE wyniosła 92% i była niezależna od BMI. Otyłość miała jednak wpływ na ilość 
energii potrzebnej do przywrócenia rytmu zatokowego (150 J w NOG vs. 200 J w OG; p < 0,05). Skuteczność CVE oce-
niania po miesiącu wyniosła 47%: 38,8% w OG i 60,6% w NOG (p < 0,05). Pacjenci w OG charakteryzowali się większymi 
wymiarami lewego przedsionka, lewej komory i niższą frakcją wyrzutową lewej komory (LVEF) w porównaniu z NOG 
(p < 0,05). Analiza regresji wykazała, że LVEF istotnie wpływa na skuteczność CVE ocenianej po miesiącu obserwacji 
(iloraz szans: 1,107, 95% CI: 1,015–1,207; p < 0,05).
Wnioski. Otyłość wydaje się nie wpływać na natychmiastową skuteczność CVE, jednak rzutuje na wartość energii 
koniecznej do przywrócenia rytmu zatokowego. Skuteczność CVE oceniania po miesiącu jest niska, a współistnienie 
otyłości dodatkowo zmniejsza szanse na utrzymanie rytmu zatokowego.
Słowa kluczowe: otyłość, migotanie przedsionków, kardiowersja elektryczna, przywrócenie rytmu zatokowego, energia 
kardiowersji elektrycznej
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